San Antonios Resources Inc. Announces Letter of Intent to Acquire Medical DeviceTechnology and Debt Settlement Agreement.

Business Editors

VANCOUVER, British Columbia--(BUSINESS WIRE)--Aug. 30, 2002

SanAnto (OTCBB:SATRF) Planned Acquisiton: San Antonios Resources, Inc., ("the Company") has entered into a Letter of Intent with Global Medical Sciences Inc. to acquire certain proprietary medical technology by way of the issuance of approximately 4,000,000 restricted common shares. The transaction is set to close on September 23, 2002. On closing San Antonios Resources, Inc., will enter into an exclusive worldwide Technology Licence Agreement with Global Medical Sciences to commercialize and further develop the technology known as the URO-Stent.

The current Board of Directors recognizes the need to bring in new ownership and management to move the Company's business in this new direction and has unanimously approved the terms of the proposed transaction. Shareholder approval for a change of shareholder control and for the acquisition will be sought at its Annual General Meeting as well as approval for a change of name to Global Precision Medical, Inc. The principal business of San Antonios Resources, Inc., will therefore cease to be a mining exploration company and efforts are underway to sell the remaining mining properties that are currently held through the Company's 100% owned subsidiary San Antonios Resources (USA), Inc.

Technology

Global Medical Sciences is developing a new generation of medical products using state-of-the-art stent coating and drug delivery technologies. The Company's business objective is to be a leader in devices for prostate related disorders and has developed and manufactured its first generation product - a leading edge patentable proprietary nitinol Prostatic Stent (Uro-stent) for the prevention of lumen restriction associated with benign prostate hyperplasia (BPH).

BPH is a non-cancerous enlargement of the prostate, which compresses the urethra as it grows thereby restricting the flow of urine - a primary cause of urinary voiding dysfunction in men. The stent is engineered from biocompatible Nickel/Titanium wire and is self-expanding to act as a scaffold to hold open the urethra. The stent will be sheathed on a catheter, and the resulting stent and delivery system sterilized and packaged as a ready-to-use unit. The non-invasive implantation procedure will be carried out on an outpatient basis, typically under local anesthesia, to restore unobstructed urine flow.

The URO-stent has completed a comprehensive series of preclinical and clinical tests that have demonstrated safety and effectiveness of the product. San Antonios Resources, Inc., has undertaken to finance and carry out a three-phase development and commercialization program:

-- Phase I: Complete technology transfer (from Russian Academy of Science to Canadian base of operations).

-- Phase II: Complete reconfirmation of Russian-based clinical results via Canadian sponsored clinical study. San Antonios Resources Inc. will engage a Canadian-based Clinical Research Organization (CRO) to work in close collaboration with Russian Inventors, Engineers, Scientists and Clinicians to replicate original clinical success.

-- Phase III: To obtain "CE Mark" (Conformite Europeenne Mark) approval for this stent, which will permit marketing into the EU and certain other countries. Based on the current stage of development and testing required to market this product, the Company projects that it can obtain the CE Mark in the third quarter of 2003, with commercial manufacturing and marketing projected to start by the fourth quarter of 2003. Further international human clinical trials will be carried out for completion by the end of 2003 with US sales projected for 2005.

Market Opportunity

The worldwide benign prostate hyperplasia treatment market currently generates over US$3 billion in revenues and is projected to grow at over 15% per year. An estimated 30 million men worldwide suffer from moderate to severe symptoms. In the US, the group of men over 65 years old is expected to double over the next 15 years; an age group in which an estimated 70% have symptoms of benign prostate hyperplasia.

Debt Settlement

San Antonios Resources, Inc., has entered into a Debt Settlement agreement with two creditors to settle US$69,618.70 by way of the issuance of restricted Treasury shares at $.12.5 each for an aggregate of 556,950 shares. The closing of the shares for debt settlement will take place at the election of the Company any time on or before October 31st and such closing will be marked by the issuance of Treasury shares.

Resignation and Appointment of Director

The Company also announces that it accepted the resignation of Mr. Norman Wareham as Director and Secretary/Treasurer and has appointed Linda Holmes as Director and Corporate Secretary effective August 27, 2002.

Subsequent to completion of the transaction with Global Medical Sciences Inc., the Company contemplates a trading symbol and CUSIP number change commensurate with its new business direction. As of the date of this news release, the Company's common shares trade under the symbol "SATRF" on the OTCBB.

On behalf of the Board of San Antonios Resources, Inc.,

Linda Holmes, Corporate Secretary and Director

SAFE HARBOR STATEMENT

This news release may include forward-looking statements within the meaning of section 27a of the United States Securities Act of 1933, as amended, and section 21e of the United States Securities and Exchange Act of 1934, as amended, with respect to achieving corporate objectives, developing additional project interests, the company's analysis of opportunities in the acquisition and development of various project interests and certain other matters. These statements are made under the "safe harbor" provisions of the United States private securities litigation reform act of 1995 and involve risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements contained herein.